<DOC>
	<DOCNO>NCT00046943</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase III trial determine effectiveness atrasentan treat patient prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Atrasentan Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety atrasentan patient hormone-refractory prostate cancer . - Determine pharmacokinetics drug patient . OUTLINE : This open-label , multicenter study . Patients receive oral atrasentan daily 3 year absence disease progression unacceptable toxicity . Patients follow 1 month every 3 month 2 year . PROJECTED ACCRUAL : Approximately 1,400 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Atrasentan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis hormonerefractory prostate cancer Completed protocol ABBOTTM00211 ABBOTTM00244 within past 30 day Disease progression OR Active trial doubleblind treatment period end PATIENT CHARACTERISTICS : Age 19 Performance status Karnofsky 60100 % Life expectancy Not specify Hematopoietic WBC least 3,000/mm3 Absolute neutrophil count great 1,000/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic Bilirubin le 1.5 mg/dL AST ALT great 1.5 time upper limit normal Renal Creatinine clearance least 40 mL/min Cardiovascular No New York Heart Association class IIIV heart disease Pulmonary No significant pulmonary disease require chronic pulse steroid therapy within past 3 month Other Fertile patient must use 2 effective method contraception ( 1 must barrier contraception ) 8 week study No reason would preclude study No significant comorbid condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 4 week since prior cytotoxic chemotherapy No concurrent cytotoxic chemotherapy Endocrine therapy Not specify Radiotherapy At least 4 week since prior radionuclides No concurrent radionuclides Surgery Not specify Other At least 4 week since prior investigational agent No concurrent antiretroviral therapy HIVpositive patient No concurrent participation another investigational study</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2003</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>